Bioequivalence study of Levodopa 100 mg and Benserazide 25 mg, Levopar® Dispersible tablets manufactured by PT Meprofarm in comparison with Levodopa 100 mg and Benserazide 25 mg, Madopar® Dispersible tablets manufactured by Delpharm Milano, Italy, imported by PT Boehringer Ingelheim Indonesia, distributed by PT Roche Indonesia

Tahapan Penelitian : Complete
Sponsor:
Mitra Pelaksana:
PT Biometrik Riset Indonesia
No Registry
INA-72LKD2NO
Tanggal Input Registry : 14-04-2025

31-01-2022
AUC0-t , Cmax
AUC0-inf , Tmax, Half life
 
Bioequivalence study of Levodopa 100 mg and Benserazide 25 mg, Levopar® Dispersible tablets manufactured by PT Meprofarm in comparison with Levodopa 100 mg and Benserazide 25 mg, Madopar® Dispersible tablets manufactured by Delpharm Milano, Italy, imported by PT Boehringer Ingelheim Indonesia, distributed by PT Roche Indonesia
Bioequivalence study of Levodopa 100 mg and Benserazide 25 mg, Levopar® Dispersible tablets manufactured by PT Meprofarm in comparison with Levodopa 100 mg and Benserazide 25 mg, Madopar® Dispersible tablets manufactured by Delpharm Milano, Italy, imported by PT Boehringer Ingelheim Indonesia, distributed by PT Roche Indonesia
Interventional
Levodopa 100 mg and Benserazide 25 mg, Levopar® Dispersible tablets manufactured by PT Meprofarm
32
 

Inclusion Criteria:

a. Willing to participate and agree to sign informed consent, and be able to communicate well with the investigators. b. Healthy female/male subjects as determined by the medical screening assessments. c. Aged 18 - 55 years inclusive. d. Body mass index within the range of 18.00 - 25.00 kg/m2. e. Vital signs, after 10 minutes resting, within the following ranges: (i). Pulse rate: 60 - 90 bpm. (ii). Respiratory rate : 12 – 20 x/minutes. (iii). Systolic blood pressure: 100 - 130 mmHg. (iv). Diastolic blood pressure: 60 - 90 mmHg. f. Have 12-lead ECG without significant abnormalities. g. Negative results of rapid test antigen Covid-19 in screening process.

Exclusion Criteria:

a. Participate in another study within 3 (three) months prior to the first day of study drug administration. b. Pregnant or lactating female (urinary pregnancy test will be performed at screening day and prior to study drug administrations on each period). c. Smoker or smoking more than 10 (ten) cigarettes per day. d. Intake of any prescription drug or non-prescription drug within 7 days prior the first day of drug administration of this study. e. Blood donation or blood loss of 300 mL (or more) within 3 (three) months prior to the first day of study drug administration. f. History of drug and/or alcohol abuse or dependency within 12 months prior to the first day of study drug administration. g. Known hypersensitivity or contraindication to the study drug. h. Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study, e.g. gastrointestinal disease including gastric or duodenal ulcers or history of gastric surgery. i. History of any bleeding or coagulative disorders. j. The presence/History of previous psychiatric disorders k. Clinically significant hematology abnormalities. l. Clinically significant urinalysis abnormalities. m. Renal insufficiency (plasma’s creatinine concentration ≥ 1.50 mg/dL). n. History or presence of any liver dysfunction (SGPT, alkaline phosphate, total bilirubin ≥ 1.5 ULN).o. Positive result of HBsAg, HCV, and/or HIV test.
 
KET-288/UN2.F1/ETIK/PPM.00.02/2021 untuk versi 1.00 S-587/UN2.F1/ETIK/PPM.00.02/2021 untuk versi 1.01 S-775/UN2.F1/ETIK/PPM.00.02/2021 untuk versi 1.02 S-885/UN2.F1/ETIK/PPM.00.02/2021 untuk versi 1.03
Not applicable
PPUK/PPUB number
075/BE/NOV-2020
Oktaviani Utami Dewi, S.Si - Ass. Manager QA Telp : 0853-2128-8082 e-Mail: oktaviani@biometrikriset.com